advanced AND "prostate cancer" AND (hasabstract[text] AND "last 180 days"[PDat] AND (Humans[Mesh]) AND (Male[MeSH Terms]))

Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.

Park SY, Wilkens LR, Franke AA, Le Marchand L, Kakazu KK, Goodman MT, Murphy SP, Henderson BE, Kolonel LN.

Br J Cancer. 2009 Jul 7;101(1):185-91. Epub 2009 Jun 16.

PMID: 19536097 [PubMed - indexed for MEDLINE]

Duration of androgen suppression in the treatment of prostate cancer.

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.

N Engl J Med. 2009 Jun 11;360(24):2516-27.

PMID: 19516032 [PubMed - indexed for MEDLINE]

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. Epub 2009 Jun 9. Review.

PMID: 19509232 [PubMed - indexed for MEDLINE]

Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.

Ricart AD, Sarantopoulos J, Calvo E, Chu QS, Greene D, Nathan FE, Petrone ME, Tolcher AW, Papadopoulos KP.

Clin Cancer Res. 2009 Jun 1;15(11):3866-71. Epub 2009 May 19.

PMID: 19458055 [PubMed - indexed for MEDLINE]

Challenges in clinical prostate cancer: role of imaging.

Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group.

AJR Am J Roentgenol. 2009 Jun;192(6):1455-70.

PMID: 19457806 [PubMed - indexed for MEDLINE]

Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.

Balanathan P, Williams ED, Wang H, Pedersen JS, Horvath LG, Achen MG, Stacker SA, Risbridger GP.

Br J Cancer. 2009 Jun 2;100(11):1784-93. Epub 2009 May 12.

PMID: 19436293 [PubMed - indexed for MEDLINE]

Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial.

Morey MC, Snyder DC, Sloane R, Cohen HJ, Peterson B, Hartman TJ, Miller P, Mitchell DC, Demark-Wahnefried W.

JAMA. 2009 May 13;301(18):1883-91.

PMID: 19436015 [PubMed - indexed for MEDLINE]

De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population.

Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, Woodle ES.

Transplantation. 2009 May 15;87(9):1347-59.

PMID: 19424035 [PubMed - indexed for MEDLINE]

ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population.

Kalay E, Ergen A, Narter F, Agaçhan B, Görmüs U, Yigit N, Isbir T.

Anticancer Res. 2009 Apr;29(4):1395-8.

PMID: 19414393 [PubMed - indexed for MEDLINE]

10:

Phase II study of sunitinib in men with advanced prostate cancer.

Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR.

Ann Oncol. 2009 May;20(5):913-20.

PMID: 19403935 [PubMed - indexed for MEDLINE]

11:

DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Hoque MO.

Expert Rev Mol Diagn. 2009 Apr;9(3):243-57. Review.

PMID: 19379083 [PubMed - indexed for MEDLINE]

12:

Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?

Wadhwa VK, Parr NJ.

Urology. 2009 Jun;73(6):1347-51. Epub 2009 Apr 10.

PMID: 19362345 [PubMed - indexed for MEDLINE]

13:

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. Epub 2009 Apr 9.

PMID: 19359544 [PubMed - indexed for MEDLINE]

14:

Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TM, Jelescu-Bodos AE, Blaszczyk N, Vessella RL, Masri BA, Sadar MD.

Cancer Res. 2009 Apr 15;69(8):3433-42. Epub 2009 Apr 7.

PMID: 19351846 [PubMed - indexed for MEDLINE]

15:

Optimizing molecular signatures for predicting prostate cancer recurrence.

Sun Y, Goodison S.

Prostate. 2009 Jul 1;69(10):1119-27.

PMID: 19343730 [PubMed - indexed for MEDLINE]